Large-scale HIV vaccine trial discontinued early
Scientist are now grappling with the big question as to why the South African trial of an HIV vaccine has behaved differently to a similar trial in Thailand. The early abandonment of the HVTN 702 study, also known as Uhambo was announced this week for failing to prevent infections, a huge setback in the quest to find a vaccine for HIV. Researchers are however adamant that this will not deter efforts to find a vaccine for the infection. For further clarity on the halting of the trial that was due to run until 2022, Channel Africa's Jane Rabothata spoke to University of Cape Town's Professor Linda-Gail Bekker, who is one of the researchers..